Royalty Report: Drugs, Vaccine, Cancer – Collection: 248332

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Vaccine
  • Cancer
  • Disease
  • Immune
  • Therapeutic
  • Delivery
  • DNA
  • Antibody
  • Alzheimer’s disease
  • HIV / AIDs
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248332

License Grant
Licensor grants to Licensee a non-exclusive license, with the right to grant sublicenses, under the Technology, and to use the Immune Modulator in connection therewith, in each case to make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Products in the Field in the Territory.
License Property
Licensor is the owner or licensee of certain rights, title, and interests in, and know-how related to, proprietary technologies involving immunomodulatory oligonucleotides.

Immune Modulator shall mean Coleys proprietary immunomodulatory oligonucleotide whose confidential sequence has been identified by Licensor as CpG 7909.

Licensed Product shall mean a product labeled for use in the Field and consisting of Immune Modulator, up to a maximum dose of 2 mg per administration, coformulated with one or more Antigens in a single vial; syringe or other suitable container.

VaxImmune™ is one member of Coley’s family of CpG TLR9 agonists, which are short synthetic DNA-like sequences that invoke potent innate and adaptive immune responses of the body’s immune system, comprised of both antibody- and cell-mediated pathways. Recent published scientific research by independent researchers have demonstrated that VaxImmune™ vaccine adjuvants are suitable for use in both prophylactic and therapeutic vaccines and can elicit a powerful immune response against infectious disease and cancers.

Field of Use
The Field shall mean the use of Immune Modulator co-formulated with one or more Antigens as a vaccine that is labeled solely for use as a prophylactic administered via a Specified Delivery Method to prevent one or more Specified Diseases in humans.

VaxImmune is known as a vaccine adjuvant, used in conjunction with a vaccine to improve immune responses and make the vaccine more effective.

IPSCIO Record ID: 212650

License Grant
The Licensor grants to Licensee a non-exclusive, royalty-bearing license, with the right to grant sublicenses, under the Patents to Exploit the Licensed Product in the Field in the Territory and to Manufacture or have Manufactured the Compound in connection with such Exploitation of the Licensed Product.  Field shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans.  Delivery Method for the Licensed Product shall mean intramuscular or subcutaneous delivery.
License Property
The Licensor is the owner or licensee of certain rights in proprietary technologies involving immunomodulatory oligonucleotides.

“Licensed Product” shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.

Patents Claiming Priority to Patent Application Serial No. 08/276,358

Field of Use
“Field” shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans. The Field specifically excludes any product for the prevention of disease, indications or disorders other than Hepatitis B Virus in humans and any product for the treatment of any disease, indications or disorders.

IPSCIO Record ID: 203335

License Grant
Licensor grants to the German Licensee a worldwide exclusive license under the patent rights to make and have made, to use and have used, to import and have imported, to offer for sale and have offered for sale, and to sell and have sold the Licensed Products, and to practice the Licensed Processes in the Field. Such license shall include the right to grant further sublicenses,

Licensee accepts a worldwide non-exclusive license to make and have made, to use and have used, to import and have imported, to offer for sale and have offered for sale, and to sell and have sold Oligonucleotides solely for any and all preclinical and research purposes, the additional products.

Licensor grants an exclusive, worldwide license, with the right to sublicense, to all improvements conceived or made during such term by Licensor employees or consultants or any other third party working for, on behalf of or under the supervision of, Licensor, and any patent rights claiming such improvements including any continuations, divisionals, reexaminations, reissues or extensions of any such patent rights, and any and all foreign patents and patent applications corresponding thereto, to the extent they relate to animal and/or veterinary applications and uses for Oligonucleotides.

License Property
The Oligonucleotides are solely for any and all preclinical and research purposes.

Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.

Field of Use
The Field shall mean any use of Licensed Products or Licensed Processes in animal and/or veterinary uses including both those requiring approval by a Regulatory Authority and those which do not require approval by a Regulatory Authority, including but not limited to use in or as animal feed.

IPSCIO Record ID: 279339

License Grant
Licensor Technology.  Licensor hereby grants to Licensee and Licensee hereby accepts a worldwide, non-exclusive license in the Fields and in the Territory under the Licensor Technology, with a right to sublicense, to (a) make, have made, use, export and import CpG 7909, and sell CpG 7909 to a Licensee Affiliate or Related Party and (b) make, have made, use, offer to sell, sell, export and import Product(s).

Non-Exclusive License Grant. In the event that the making, having made, use, offer for sale, sale, export or import by Licensee, or Licensee’s Related Parties, of CpG 7909 or Product(s) would infringe, during the term of this Agreement, a claim of issued letters patent which Licensor owns or has the rights to license and which patents are not covered by the grant, Licensor hereby grants to Licensee a non-exclusive, sublicensable, royalty-free license in the Territory under such issued letters patent for Licensee and its Related Parties to make, have made, use, sell, offer for sale, export and/or import CpG 7909 and Product(s) in the Field and in the Territory.

Grant-back License.  Licensee will grant to Licensor a non-exclusive, royalty-free, fully-paid up, perpetual worldwide license, including the right to grant sublicenses, to any Licensee Patent arising under the Agreement, which claims recite the use, formulation or any other Improvements solely related to the licensed Licensor Technology (each a “LicensorTechnology Improvement”) to the extent necessary for Licensor and its sublicensees to practice Licensor Technology Improvements outside the Fields.

License Property
Product means any Vaccine which contains CpG 7909 co-formulated with one or more Antigen using the Delivery Method for any and all uses in a Field, whether such Product is for sale by prescription, over-the-counter or by any other method or for use in a Clinical Trial. Product includes any Vaccine which contains CpG 7909 that is being Developed under this Agreement for Marketing Authorization as well as Additional Products for which the Option hereunder has been exercised. For purposes of clarity, no Product may be Developed for the prevention, treatment or control of any cancer nor may any Clinical Trial be conducted with a Product with clinical endpoints of prevention, treatment or control of any cancer.

CpG 7909 means the Adjuvant Controlled by Licensor that is a proprietary immunomodulatory oligonucleotide containing unmethylated cytosine and guanine dinucleotides whose sequence has been defined by Licensor as CpG 7909 which acts as an agonist of toll-like receptor 9 to modulate the immune response.

Additional Product means any Vaccine which contains CpG 7909 co-formulated with one or more Antigen using the Delivery Method for any and all uses in an Additional Field for which Licensee has exercised its Option under this Agreement.

Licensor Patent Right(s) means all Patent Rights Controlled by Licensor as of the Effective Date, including those listed, or Controlled by Licensor during the Term of this Agreement, which claim or cover CpG 7909 or the use, formulation or Manufacture of CpG 7909 or Products in the Territory.

US 6,194,388 – Immunomodulatory oligonucleotides
US 6,429,199 – Immunostimulatory nucleic acid molecules for activating dendritic cells
US 7,001,790 – Light-emitting aluminum gallium indium nitride compound semiconductor device having an improved luminous intensity

License Patents means any and all issued patents in the Territory which during the Term of this Agreement are Controlled by Licensee or its Controlled Affiliates, which (a) claim or cover Product or (b) which claim or cover a use, formulation or method of manufacture solely related to the licensed Licensor Technology.

Field of Use
Fields means all uses in humans of Vaccines that is indicated and/or used for the following Indications (each of which constitutes a Field)
a. Prevention of Infection with Hepatitis B Virus
b. Prevention of Infection with Seasonal Interpandemic Influenza Virus
c. Prevention of Infection with Pandemic Influenza Virus
d. Treatment of Alzheimers Disease
Field also includes any Additional Field for which Licensee has exercised the Option under.

IPSCIO Record ID: 368651

License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.

The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.

Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.

Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.

TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products.  This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.

The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.

This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).

IPSCIO Record ID: 203333

License Grant
This amendment restates the field, the product, the patent rights and royalties.  In the original agreement, the Canadian Licensor grants an exclusive license in the Field and in the Territory to utilize the Licensed Technology and to develop, have developed, make, have made, perform, use, have used, sell, offer for sale, have sold, import or have imported Licensed Products.
License Property
With this amendment, the product is restated.  Licensed Product shall mean any product or process which is covered, on a country-by-country and product-by-product basis, by a Pending or issued claim under Patent Rights in such country. In addition, Licensed Product shall also mean, on a product-by-product basis, any product or process not covered by Patent Rights which to a material degree, as determined by mutual agreement of the Parties, contains, is based on, or is derived from, identified through or utilizes any Licensed Technology which is not in the public domain. Any product or process which is a Licensed Product at the time of first Commercial Sale shall be treated as a Licensed Product for at least 10 years from the date of first Commercial Sale.

The amended patent applications are for Methods and Products for Inducing Mucosal Immunity, Immunostimulatory Nucleic Acids for Inducing a Th2 Immune Response, Encapsulation of CpG ODN into Calcium Phosphate (CAP) Nanoparticles, Use of Light Biovector System for Intranasal Delivery of CpG ODN- containing vaccines, Use of Nucleic Acids containing Unmetholated CpG Dinucleotide as an Adjuvant, Vectors and Methods for Immunization for Therapeutic Protocols, Use of Nucleic Acids containing Unmethylated CpG Oligonucleotides as an Adjuvant, and, Methods for the Prevention and Treatment of Parasitic Infections and Related Diseases using Oligoucleotide.

09/316,199 (8,574,599) – Methods and products for inducing mucosal immunity

The CpG oligonucleotide is particularly useful as a prophylactic vaccine for the induction of mucosal immunity of a subject at risk of developing an infection with an infectious organism or a subject at risk of developing an allergy or cancer.

Field of Use
With this amendment, the field is restated Field shall mean any and all uses of CpG, T- rich or G- rich molecules and any derivatives, modifications, improvements, fragments, analogs, or homologs thereof and any other materials which could not have been discovered or made but for the use of the above described molecules or Licensees confidential information, whether used alone or in combination with other agents, including but not limited to, formulations or delivery systems.

IPSCIO Record ID: 249711

License Grant
Licensor grants a co-exclusive license, except non-exclusive license for HIV, in accordance with the terms stated herein.

Licensor grants to the United Kingdom Licensee and to any affiliates the following licenses, with the right to grant sublicenses, under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field all Products and/or Combinations, subject to the following
– For Prophylactic Immunization within the Field, Licensor grants a Co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• INFLUENZA ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS
• RSV ANTIGENS
• Malaria ANTIGENS

– For Prophylactic Immunization within the Field, Licensor grants a non-exclusive license for the following Licensed Antigens and no other Antigens
• HIV ANTIGENS

– For Therapeutic immunization within the Field Licensor grants a co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS

License Property
The Product shall mean any and all pharmaceutical compositions for the Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, to the extent Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of such Licensed Antigens contained within Product.

The patents relate to the use of Nucleic Acid.

Field of Use
The field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans, expressly excluding the Specific Field.

Specific Field shall mean the use of Adjuvant as part of or in conjunction with a DNA Vaccine or other than in combination with a Licensed Antigen.

IPSCIO Record ID: 380352

License Grant
Licensor grants
— an exclusive license, including the right to sublicense, under the Licensor Patent Rights to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product in the Field in the Territory,
— an exclusive license, including the right to sublicense, to use Licensor Technology and Licensor Confidential Information to the extent reasonably useful for the manufacture, use, sale, offer for sale and importation of the Compound, any Research Compound and any Licensed Product in the Field in the Territory;

Licensor grants a nonexclusive, worldwide license, including the right to sublicense, under the Licensor Patent Rights in the Field, the Licensor Technology in the Field, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import any molecule that is incidental to the manufacture and use of the Compound, any Research Compound, any Licensed Product or any Generic Product.

For the Clinical Development License, Licensor grants an exclusive license, including the right to sublicense, under the Licensor Patent Rights, the Licensor Technology, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product, for any clinical study in the Territory.

For the Research Licenses, without limiting any of the licenses granted, Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term.

License Property
Licensor owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.

Compound means ProMuneâ„¢.

Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensor.

Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.

Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.

Licensors Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.

Field of Use
The field of use includes the treatment, Control or prevention of cancer in humans.

ProMune (CPG 7909) is a toll-like receptor 9 (TLR9) agonist delivered by subcutaneous injection for the potential treatment, control and prevention of cancers in humans.

IPSCIO Record ID: 203334

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses to third parties, under the Licensor Technology and Joint Patent Rights, to the extent necessary to make, have made, and use the Selected Immune Modulators to develop, make, have made, use, sell, have sold, offer for sale, and import the Products in the Field, including the right to make, have made, use, sell, have sold and import metabolites incidental to the manufacture, storage, and use of Products in the Field, in the Territory, and, an exclusive license, including the right to grant sublicenses to third parties or approved in writing by Licensor, under the Licensor Technology and Joint Patent Rights, to the extent necessary for Licensee to perform in vivo testing during the Option Term,  on the up to twenty-eight (28) Immunomodulatory Oligonucleotides run through Step 2, and an exclusive license, including the right to grant sublicenses to third parties, under the Licensor Technology and Joint Patent Rights to perform research and development on the Licensee Immune Modulators in order to select the Selected Immune Modulators.

In the event Licensee determines that it would like to grant a sublicense in a Major Market Country with respect to any of the rights granted by Licensor, Licensor shall have a right of first negotiation to obtain such sublicense.

Licensees right to grant sublicenses in any country other than a Major Market Country with respect to any of the rights granted by Licensor hereunder shall be subject to Licensor’s prior written consent.

License Property
The technology and patents relate to Immune Modulators.  The Product shall mean a drug product consisting of at least one Selected Immune Modulator formulated as a monotherapy or a Combination Product.  Immune Modulators shall mean CpG 7909, CpG 7279 and the Licensee Immune Modulators.
Field of Use
Field shall mean the use of Immune Modulators solely for prophylactic and/or therapeutic treatment of asthma, allergic rhinitis or COPD, administered via a Delivery Method. The Field specifically excludes, without limitation the use of Immune Modulators for all other allergic indications, atopic indications, autoimmune disorders and/or inflammatory disorders; and/or any administration of Immune Modulators other than via a Delivery Method; and/or any and all drug combinations incorporating any antigens, including without limitation allergens, for asthma, allergic rhinitis, COPD or for any other indication, whether the materials comprising such combinations are administered simultaneously or separately at different sites or times, and/or (iv) any and all drug combinations incorporating any medications, monoclonal antibodies, or other agents unless such medications, monoclonal antibodies or other agents are for the prophylactic and/or therapeutic treatment of asthma, allergic rhinitis or COPD, or such other agents are formulations with excipients, carriers, or delivery vehicles whether the materials comprising such combinations are administered simultaneously or separately at different sites or times.

IPSCIO Record ID: 372620

License Grant
Licensor grants an exclusive license in the Territory under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to use, offer to sell, sell or import the Licensed Vaccine and/or the Products for any and all uses in the Field.

Licensor grants an exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the Territory other than the United States, for any and all uses in the Territory in the Field.

Licensor grants a non-exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the United States, for any and all uses in the Territory in the Field.

For the Non-Exclusive License Grant, in the event that the making, having made, use, offer for sale, sale or import by Licensee, or its Related Parties, of Licensed Vaccine or Products would infringe during the term of this Agreement a claim of issued letters patent which Licensor owns and which patents are not covered by the grant, Licensor grants, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable license in the Territory under such issued letters patent for Licensee and its Related Parties to develop, make, have made, use, sell, offer for sale or import Licensed Vaccines and Products in the Territory.

If Licensee desires to use any trademark identified by Licensor as of the Effective Date for use for the Licensed Vaccine and/or Product in the Territory, it will include without limitation the trademark Heplisavâ„¢.

License Property
Licensed Vaccine shall mean a pharmaceutical or biological preparation that contains both the Hepatitis B Surface Antigen and IO 18 ISS for prophylactic use that elicits an immune and/or protective response.

Hepatitis B Surface Antigen shall mean an immunogenically effective Hepatitis B Surface Antigen protein that is produced by recombinant DNA technology.

x-ISS shall mean the adjuvant, an immunostimulatory sequence (ISS) composed of the 22mer phosphorothioate oligonucleotide sequence 5 TGA CTG TGA ACG TIC GAG ATG A3.

Patents and know-how include
ISSs, Compositions and Methods of Use;
DNA Molecules Coding for FMDH Control Regions; and,
Immunostimulatory Nucleic Acid Molecules.

The trademark is Heplisavâ„¢.

Field of Use
The Field shall mean with respect to Products that are not Combination Products, the Hep B Field, and with respect to Combination Products, the prevention of diseases for any and all purposes, including without limitation the Hep B Field.

Heplisav-B is a vaccine used in adults 18 and over to prevent hepatitis B, a viral infection of the liver.

IPSCIO Record ID: 368652

License Grant
University of the United Kingdom grants
—   an exclusive non-transferable, except as a license in the Field under the Patents, with the right to sublicense, to research, develop, manufacture, have manufactured, use, import, offer for sale and sell Licensed Products in the Territory
—  an exclusive license in the Field to use the Know-How, with the right to sublicense, to research, develop, manufacture, have manufactured, use, import, offer for sale and sell Licensed Products in the Territory;
—  an exclusive license in the Field to use the Materials, solely for research and development purposes. For the avoidance of doubt Licensee shall not humanize any of the Materials nor administer the Materials, or any substances contacted with the Materials, to human subjects.

Licensee shall not grant sub-licenses to any Tobacco Party.

License Property
The University has determined that agonistic anti-mouse CD27 antibodies were unexpectedly potent at triggering T-cell expansion and identified the potential application of using such antibodies as vaccines for the treatment of disorders that may benefit from immune stimulation.

University has a patent application for Human Immune Therapies Using a CD27 Agonist Alone or in Combination with Other Immune Modulators.

University also has generated an agonistic anti-mouse CD27 mAb (clone AT124-1) and a selection of mouse anti-human CD27 MAb, included in the Materials.

Materials means agonistic anti-mouse CD27 mAb {clone AT124-1} and agonistic mouse anti-human C027 mAbs {clones AT133·2, AT133-4, AT133·5, AT133·6, AT133-7, AT133·11 and AT133-14) and any derivatives thereof generated by Licensee, its Affiliates or sub-licensees.

The Know-How includes Know~how in developing functional agonistic human mAb to CD27.

Field of Use
The patent and know-how license agreement is to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers.   In pre-clinical models, antibodies to CD27 alone have been shown to mediate anti-tumor effects, and may be particularly effective in combination with other immunotherapies. CD27 is a critical molecule in the activation pathway of lymphocytes. It is downstream from CD40, and may provide a novel way to regulate the immune responses. Engaging CD27 with the appropriate monoclonal antibody has proven highly effective at promoting anti-cancer immunity in mouse models. We are currently evaluating new human monoclonal antibodies in pre-clinical models.

The Field means all therapeutic or prophylactic uses. including uses as adjuvants or vaccines, in the Territory of agonistic anti-CD27 antibodies, alone or in combination with any other pharmaceutical agent, other than the Universitys Field.

Universitys field means all therapeutic or prophylactic uses, including uses as adjuvants or vaccines, in the Territory of agonistic anti-CD27 antibodies in combination with the Universitys proprietary anti-human CD40 ChiLob7.4 antibody and derivatives thereof where such use includes the in vivo administration of such anti-CD27 antibody and such anti-human CD40 ChiLob7.4 antibody to a mammal or the in vitro use of such anti-C027 antibody and such anti-human CD40 Ch1Lob7.4 antibody, wherein the two antibodies must be administered together as an approved therapeutic combination regimen.

IPSCIO Record ID: 372584

License Grant
Licensor grants a non-exclusive license, including the right to sublicense solely to Affiliates of Licensee, in the Territory under Licensor Use Patent Claims which are determined to include Infringing Claims for use in connection with Covered ODNs outside the Field to the extent otherwise not prohibited by this Agreement.

Licensor grants a non-exclusive license, including the right to sublicense to Permitted Sublicensees, in the Territory under Licensor Process Patent Claims for use in connection with the manufacture of Covered ODNs.

For the Research license,  Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term; provided that Licensee shall not have any rights to use the Licensor Technology for the sale or manufacture for sale of products or processes.

For Licensees Commercialization Rights, Licensee shall have the right to elect, upon notice to Licensor, to market the Product for the Licensees Indication to Specialty Dermatologists as provided.

License Property
The Licensed Product means any Product, Combination Product, Vaccine Product, Research Product, Research Combination Product or Research Vaccine Product.

Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensee.

Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.

Intermediate indications mean all treatment non-Hodgkins lymphoma and prostate cancer (except for Japan), all treatment of Ovarian cancer, third-line treatment of breast cancer or later treatment of breast cancer,  second-line or later treatment of NSCLC, second-line or third-line  treatment of colorectal cancer.

Minor indication means all treatment of melanoma,  T cell lymphoma, renal cell carcinoma, pancreatic cancer, hematological malignancies (other than non-Hodgkins lymphoma), bladder cancer, uterine cancer, cervical cancers and any other cancers in the field.

Licensees Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.

Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.

Field of Use
The field of use includes the treatment, control or prevention of cancer in humans.

Licensee owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.

IPSCIO Record ID: 249713

License Grant
Licensor grants to Licensee of the United Kingdom a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain any of the following two Licensed Antigens
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.

In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens
• Any and all Antigens expressed in Lung Cancer

License Property
The Product shall mean any and all pharmaceutical compositions for Prophylactic Immunization and/or Therapeutic Immunization in the field comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, in which Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of any of such Licensed Antigens contained within Product.

The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.

Field of Use
The Field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for the purpose of inducing, augmenting, fine-tuning or enhancing in vivo, in vitro or ex vivo of an Antigen specific immune response and in all cases for Prophylactic Immunization and/or Therapeutic Immunization against Licensed Cancers in humans, excluding Specific Field.

Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.

IPSCIO Record ID: 233439

License Grant
The Swiss Licensor grants a non-exclusive license under the adr-HBsAg Technology, with the right to sublicense, to research, develop, manufacture, have manufactured, market, distribute, import, use, offer for sale and sell Vaccines in the Territories for use solely in the Disease Field. Such license grant does not permit the transfer by Licensee to any third party of adr-HBsAg other than as part of assembled
Vaccines, including, without limitation, transfer of Vaccines to third parties for preclinical testing, toxicology, or clinical trials, without the prior written approval of Berna, such approval not to be unreasonably withheld.  The license granted is specific to the Disease Field.

Licensor grants the right to sublicense the right to research, develop, manufacture, have manufactured, market, distribute, import, use, offer for sale and sell Vaccines in the Territories under the adr-HBsAg Technology in the Disease Field.

License Property
adr-HBsAg shall mean the hepatitis B surface antigen of the subtype adr produced with the Hansenula polymorpha Expression System.

Therapeutic Vaccine shall mean a therapeutic hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilises additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.

Prophylactic Vaccine shall mean a prophylactic Hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilizes additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.

Field of Use
Disease Field shall mean the field of inducing an active, long term prophylactic response or therapeutic immune response against Hepatitis B, including chronic status, in humans.

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.

IPSCIO Record ID: 279292

License Grant
For the Licensed Intellectual Property, Licensor grants the exclusive, even as to Licensor, a worldwide, nontransferable right and license, with the right to grant sublicenses, under the Licensed Intellectual Property, to use, have used, sell, have sold, offer to sell, import, have imported, make and have made, and otherwise research, Develop, Commercialize or manufacture any Licensed Vaccine and/or Licensed Product, during the Term, in the Territory in the Field.

For the Trademarks for Licensed Products. To the extent that Licensor owns any Trademark(s) that pertain specifically to a Licensed Vaccine or Licensed Product, Licensor grants an exclusive right and license, with the right to grant sublicenses to Trademark(s) Controlled by Licensor solely for use with respect to such Licensed Vaccine or Licensed Product, as the case may be.

License Property
Licensor has expertise in drug discovery, development, and manufacturing of yeast-based immunotherapeutics known as Tarmogen® products.

Licensor has rights under certain patent rights and know-how rights relating to Tarmogens.

Licensed Product means any product in final form that contains a Licensed Vaccine as a therapeutically or prophylactically active ingredient.

Combination Product means any product sold in a particular country that contains a Licensed Vaccine in combination with one (1) or more other therapeutically active ingredients or drug delivery technology, devices, equipment or other components, as applicable, or formulated or packaged separately but sold together for a single price.

Field of Use
The collaboration is for the prevention and/or treatment of hepatitis B virus infection and its sequelae.  The goal of the research collaboration is to create and develop therapeutic vaccine products that have specific HBV DNA antigens cloned into S. cerevisiae (a species of yeast).

The Field means, any and all human diseases and conditions, except the treatment of any malignancy; provided, however, that Field shall include [the treatment, palliation, diagnosis and/or prevention of hepatitis that may result in the prevention and/or reduction in frequency and incidence of any and all sequelae of hepatitis infection, including the prevention and/or reduction in the frequency and incidence of hepatocellular carcinoma in patients who have co-existing hepatocellular carcinoma.

IPSCIO Record ID: 248397

License Grant
For the exclusive license, Licensors of the United States, Canada and Germany grants to Licensee, an exclusive license, including the right to sub license, under the Licensor Patent Rights to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product in the Field in the Territory, and,  an exclusive license, including the right to sublicense, to use Licensor Technology and Licensor Confidential Information to the extent reasonably useful for the manufacture, use, sale, offer for sale and importation of the Compound, any Research Compound and any Licensed Product in the Field in the Territory.

For the non-exclusive license, Licensor grants a nonexclusive, worldwide, including the right to sublicense, under the Licensor Patent Rights in the Field the Licensor Technology in the Field, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import any molecule that is incidental to the manufacture and use of the Compound, any Research Compound, any Licensed Product or any Generic Product.

For the Clinical Development License, Licensor grants an exclusive license, including the right to sublicense, under the Licensor Patent Rights, the Licensor Technology, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import the Compound, an Research Compound and an Licensed Product, for an clinical study in the Territory.

For the Research Licenses, Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term; provided that Licensee shall not have any right to use the Licensor Technology for the sale or manufacture for sale of products or processes.

License Property
Licensor owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.
Field of Use
Field means for the treatment, control or prevention of cancers in humans, melanoma, ground glass opacity, and, colon polyps; and, dermatological Disease, any skin disease that is not cancer and infectious disease.

IPSCIO Record ID: 203331

License Grant
The University grants to Licensee a worldwide exclusive license under the Patent rights to make and have made, to use and have used, to import and have imported, to offer for sale and have offered for sale, and to sell and have sold the Licensed Products, and to practice the Licensed Processes. Such license shall include the right to grant sublicenses.
License Property
The patent application is for Immunomodulatory Oligonucleotides.  The Licensed Processes shall mean the processes claimed in the Patent Rights or some portion thereof.

United States Patent Application Serial No 08/276,358

Field of Use
This agreement is for use in the human field and the animal field.

IPSCIO Record ID: 345562

License Grant
English Licensor granted a nonexclusive license to Licensee to produce and characterize potential product candidates using the Company’s viral vector technology and to provide research services to Licensee during the research term which commenced on June 2019 through the end of 66 months and for up to six vaccine products based on antigens discovered via Licensee’s proprietary platform.
License Property
Viral vector technology is known as ChAdOx1 and ChAdOx2.  This platform comprises several components that, when combined, allow the developed product candidates designed to induce high and durable levels of antigen-specific T cells and B cells, to prevent and treat infectious diseases and cancer.

ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.

Field of Use
Field of use is for the immunotherapy and vaccine fields.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.